Skip to content

High Versus Low Blood-Pressure Target in the Post Operative Care of Liver Transplantation A Randomized, Controled, Open and Unicentric Trial.

High Versus Low Blood-Pressure Target in the Post Operative Care of Liver Transplantation

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05068713
Acronym
LIVER-PAM
Enrollment
174
Registered
2021-10-06
Start date
2021-08-24
Completion date
2024-01-05
Last updated
2024-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplant; Complications

Brief summary

LIVER PAM A randomized, controled, open and unicentric trial comparing high (MAP 85-90 mmHg) and low (65-70 mmHg) target of mean arterial pressure in the first 24 hours after liver transplantation.

Interventions

OTHERUsual Care + High Target of Mean Arterial Pressure

Targeting the weaning of vasopressors to a mean arterial pressure of 85-90mmHg in the first 24h after liver trasnplant.

OTHERUsual Care

Targeting the weaning of vasopressors to a mean arterial pressure of 65-70mmHg in the first 24h after liver trasnplant.

Sponsors

University of Sao Paulo General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Older than 18 y * Admitted in the ICU for a post operative care after liver transplant

Exclusion criteria

* Consent refusal * Liver transplant due to acute liver failure * Renal transplant ( Previous or concomitant) * Refusal from the healthcare provider responsible for the patient * Renal substitution therapy in the prior 15 days * Pregnancy * Re-Transplant (Liver transplant in the previous 6 month) * Hepatorenal syndrome current treatment (Use of terlipressin + Albumin) * Refractory and persistent shock during or after transplant

Design outcomes

Primary

MeasureTime frameDescription
incidence of Acute Kidney Disfunction7 daysIncidence of acute kidney Disfunction according to kdigo criteria.

Secondary

MeasureTime frameDescription
re-transplant28 dayspercentage of re-transplant in 28 days
Lenght of Hospitay Stay28 daysLOS in 28 days
Lenght of ICU Stay28 daysICU LOS in 28 days
Days alive and out of hospital in 28 days28 daysNumber of days alive and out of hospital in 28 days
Substitutive Renal Therapy7 dayspercentage of TSR in 7 days
Days Alive and free of renal disfunction28 daysDays Alive and free of renal disfunction in 28 days
Acute kidney insufficiency according to Urinary NGAL on d0 and D20d and 2dPercentage of renal disfunction according to NGAL criteria on D0 and D2
Mortality28 dayspercentage of mortality in 28 days
Liver graft primary disfunction ( Initial Poor Function)7 dayspercentage of Initial Poor Function in 7 days
Liver graft primary disfunction (primary nonfunction)10 dayspercentage of primary nonfunction in 10 days
Surgical site infection28 dayspercentage of SSI in 28 days
Need of Transfusion7 dayspercentage of Transfusion requirement in 7 days
Postoperative Major bleeding in 7 days7 daysBleeding that requires 2 units of blood transfusion in a single day or the need of a reoperation due to bleeding in the first 24 hours after surgery.
Incidence of Arrythmia requiring clinical treatment7 dayspercentage of Arrhythmia requiring treatment in 7 days
MAKE2828 daysMajor Kidney Events ( Death, persistent acute kidney disfunction or need of RRT in 28 days)

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026